A short-acting benzodiazepine and the TCCC-doctrine anticonvulsant and procedural sedation agent. Midazolam's rapid onset (especially IN and IM), short duration, and water solubility (no propylene glycol vehicle) make it the field benzodiazepine of choice. Standard TCCC use: seizure termination, severe agitation in TBI, ketamine sedation adjunct, and procedural sedation.

Pharmacology and Actions

Midazolam is a short-acting benzodiazepine that potentiates GABA-A receptor activity at the benzodiazepine binding site, enhancing chloride conductance and producing CNS depression. Effects include sedation, anxiolysis, anterograde amnesia, anticonvulsant activity, and muscle relaxation. Water-soluble at acidic pH (formulated at pH 3.5), becoming lipid-soluble at physiologic pH after injection - this rapid lipid solubility shift is what makes midazolam's onset so fast compared with diazepam or lorazepam.

Indications

Status epilepticus and acute seizure termination (TCCC doctrine)
Severe agitation in TBI casualty (TCCC indication)
Procedural sedation (intubation, fracture reduction, painful procedures)
Ketamine sedation adjunct (reduces emergence reactions)
Preoperative sedation
ICU sedation for mechanically ventilated patients

Absolute Contraindications

Known hypersensitivity to midazolam or benzodiazepines
Acute narrow-angle glaucoma
Severe respiratory depression (relative; depends on clinical context)

Precautions and Side Effects

Common: respiratory depression (dose-dependent, more rapid onset than diazepam), hypotension, sedation, amnesia (anterograde), paradoxical excitation (especially in elderly and children, rare). Cardiovascular: hypotension at higher doses, especially with concurrent opioids. CNS: prolonged sedation in renal/hepatic impairment due to accumulation of active metabolite (alpha-hydroxymidazolam). Tolerance and dependence with chronic use; withdrawal symptoms after prolonged ICU sedation. Drug interactions: additive respiratory depression with opioids (most clinically important - fentanyl plus midazolam is a high-risk combination requiring respiratory monitoring); CYP3A4 inhibitors (azole antifungals, macrolide antibiotics, protease inhibitors) significantly increase midazolam levels; alcohol potentiates respiratory depression. Half-life 1.5 to 2.5 hours, prolonged in renal failure, hepatic failure, elderly, and obesity. Pregnancy Category D (avoid in late pregnancy; neonatal withdrawal). Passes into breast milk. Reversal: flumazenil 0.2 mg IV, repeated to max 1 mg - but reversal can precipitate seizures in chronic benzodiazepine users and in mixed overdoses. Schedule IV controlled substance - chain of custody and secured storage required.

Adult Dosing

IV / IO

Seizure termination: 0.1 to 0.2 mg/kg IV (typical adult dose 5 to 10 mg) slow push, repeat in 5 minutes if needed. Procedural sedation: 0.5 to 2 mg IV, titrate to effect (max 5 mg per typical episode without escalation to anesthesia management). Status epilepticus: 0.2 mg/kg IV bolus, then 0.05 to 0.4 mg/kg/hour infusion in refractory cases. Onset: 1 to 5 minutes

Seizure termination: 10 mg IM (TCCC-doctrine dose for adult; standard for prehospital status epilepticus per RAMPART trial). Procedural use: 0.07 to 0.08 mg/kg IM (typical 5 mg) 30 to 60 minutes before procedure. Onset: 5 to 15 minutes

Seizure termination: 10 mg IN (5 mg per nostril using atomizer) - TCCC and prehospital first-line route when IV access not immediately available. Bioavailability approximately 50 to 70 percent. Onset: 5 to 10 minutes

Procedural premedication: 7.5 to 15 mg PO 30 to 60 minutes before procedure (pediatric formulation more commonly used). Onset: 10 to 30 minutes

Pediatric Dosing

Seizure termination IM: 10 mg if over 13 kg (one syringe); 5 mg if 13 to 40 kg per RAMPART. IN: 0.2 mg/kg (max 10 mg). IV: 0.05 to 0.1 mg/kg slow push. Procedural sedation: 0.05 to 0.1 mg/kg IV (max 5 mg).

Pharmacokinetics

Peak Effect: IV: 3 to 5 minutes. IM: 15 to 30 minutes. IN: 10 to 15 minutes.

Duration: 30 minutes to 2 hours (single dose). Prolonged with repeated dosing or infusion due to context-sensitive half-time.

Storage and Handling

Schedule IV controlled substance - secured storage required, chain of custody documentation, log all administrations and waste. Store at room temperature (15 to 30 degrees C). Protect from light. Stable in standard EMS and tactical environments. Prefilled syringes and autoinjectors (Seizalam, Nayzilam) available for rapid field deployment.

Reconstitution:

Available as 1 mg/mL and 5 mg/mL solutions. For IV bolus: can give undiluted slow push over 2 minutes. For infusion: dilute in NS or D5W to 0.5 mg/mL (typical 100 mg in 200 mL). For IN administration: use 5 mg/mL concentration with mucosal atomization device; split dose between nostrils for volumes over 1 mL. IM: undiluted, deep muscular injection. Nayzilam is a single-use IN spray (5 mg per spray, may repeat once after 10 minutes). Seizalam is a prefilled IM autoinjector (10 mg).

TCCC and TECC Role

Midazolam is core TCCC doctrine. TCCC 2026 Guidelines specify midazolam as the first-line agent for: (1) seizure termination in casualties experiencing seizures (including post-TBI seizures, toxic exposures, and primary seizure disorders), with the IN or IM route preferred when IV access not immediately available; (2) severe agitation in TBI casualties when behavioral management is required for safe evacuation; (3) ketamine sedation adjunct to reduce emergence phenomena. Adult dose 10 mg IM/IN is doctrine. The casualty is by definition non-operational once requiring midazolam; pre-administration assessment must include airway plan due to respiratory depression risk.

Field Context

Midazolam is one of the most operationally useful medications in the TCCC formulary. The IM and IN routes provide rapid onset without requiring IV access - critical in actively seizing casualties or severely agitated TBI patients where IV placement may be impossible or dangerous. The RAMPART trial established 10 mg IM midazolam as at least as effective as IV lorazepam for prehospital status epilepticus, fundamentally changing seizure management in EMS and combat settings. Always anticipate respiratory depression after midazolam administration - have BVM ready, monitor SpO2 continuously, and plan for airway management. The combination of midazolam and fentanyl (both potent respiratory depressants) requires particular vigilance and is a known cause of preventable peri-evacuation deaths.

Common Mistake

Underdosing for seizure termination. The TCCC-doctrine adult dose is 10 mg IM/IN, not 2 to 5 mg. The 2 to 5 mg dose is appropriate for procedural sedation in a hemodynamically stable patient; it is inadequate for status epilepticus. The other common mistake is administering midazolam alongside fentanyl without enhanced respiratory monitoring - the combination produces synergistic respiratory depression that exceeds the additive effect of either agent alone. The third mistake is failing to anticipate hypotension when midazolam is given to a hypovolemic trauma casualty; the vasodilatory effect can be substantial in a patient already operating at the edge of perfusion.

Last Reviewed May 14, 2026

Reviewer TCCC 2026 Guidelines (01 May 2026); FDA labeling for Versed, Nayzilam, and Seizalam; NREMT Paramedic Drug List.

Drug Class Sedative - Benzodiazepine

DEA Schedule Schedule IV

Mission Impact Not Applicable - Patient Already Non-Operational

Reference Category TCCC Doctrine, Standard EMS, Hospital / Critical Care

Generic Name Midazolam hydrochloride

Source: Tactical Combat Casualty Care (TCCC) Guidelines, 01 May 2026, Committee on Tactical Combat Casualty Care, Joint Trauma System. FDA prescribing information for Versed, Nayzilam, Seizalam. AHFS Drug Information. RAMPART trial (Silbergleit et al., NEJM 2012) on prehospital status epilepticus.

Reference URL: https://penntacticalsolutions.com/pages/drug-reference/midazolam

Clinical Reference Notice

This drug profile is provided as educational reference material for trained medical providers. It is not medical advice, not a substitute for formal training, and not a substitute for current published guidelines or medical direction.

Drug administration is governed by your scope of practice, agency standing orders, medical director protocols, and applicable state and federal regulations. Controlled substances are subject to additional handling, accountability, and documentation requirements per DEA and state law. Always verify dosing, indications, contraindications, and route of administration against current published guidelines and your local protocols before administration.

If this content is being viewed during a medical emergency, call 911 immediately and follow the direction of your local emergency dispatch and medical control. Do not use this reference as a substitute for emergency medical services.

Drug information evolves. Last reviewed dates and source citations are provided for each entry. Confirm currency against the cited source before clinical use.

Penn Tactical Solutions publishes this reference for educational purposes. PTS does not provide medical direction and does not assume responsibility for clinical decisions made in the field. Clinical responsibility rests with the administering provider, their medical director, and their agency.

Educational reference for trained medical providers. Not medical advice. Not a substitute for formal training, current published guidelines, or medical direction. Drug administration is governed by your scope of practice, agency standing orders, medical director protocols, and applicable state and federal regulations. Controlled substances require additional storage, accountability, and documentation per DEA and state law.

In a medical emergency, call 911. This reference is not a substitute for emergency medical services.

Verify dosing, indications, and contraindications against current published guidelines and your local protocols before administration. Confirm content currency against the source citation. Penn Tactical Solutions does not provide medical direction. Clinical responsibility rests with the administering provider, their medical director, and their agency.

Midazolam

Schedule IV

Midazolam hydrochloride

Sedative - Benzodiazepine

Not Applicable - Patient Already Non-Operational

Adult Dosing

IV/IO	Seizure termination: 0.1 to 0.2 mg/kg IV (typical adult dose 5 to 10 mg) slow push, repeat in 5 minutes if needed. Procedural sedation: 0.5 to 2 mg IV, titrate to effect (max 5 mg per typical episode without escalation to anesthesia management). Status epilepticus: 0.2 mg/kg IV bolus, then 0.05 to 0.4 mg/kg/hour infusion in refractory cases. (1 to 5 minutes)
IM	Seizure termination: 10 mg IM (TCCC-doctrine dose for adult; standard for prehospital status epilepticus per RAMPART trial). Procedural use: 0.07 to 0.08 mg/kg IM (typical 5 mg) 30 to 60 minutes before procedure. (5 to 15 minutes)
IN	Seizure termination: 10 mg IN (5 mg per nostril using atomizer) - TCCC and prehospital first-line route when IV access not immediately available. Bioavailability approximately 50 to 70 percent. (5 to 10 minutes)
PO	Procedural premedication: 7.5 to 15 mg PO 30 to 60 minutes before procedure (pediatric formulation more commonly used). (10 to 30 minutes)

Pediatric

Contraindications

Known hypersensitivity to midazolam or benzodiazepines| Acute narrow-angle glaucoma| Severe respiratory depression (relative; depends on clinical context)

Common Mistake

← Back to Drug Reference